Patent intelligence · US
US 8754051
Peptide modulators of the δPKC interaction with the d subunit of F1Fo ATP synthase/ATPase and uses thereof
Peptide modulators of the δPKC interaction with the d subunit of F1Fo ATP synthase/ATPase and uses thereof
Patent details — US 8754051
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 17, 2014
- Expiration
- Jun 12, 2034
- Applicant
- Georgia Regents Research Institute, Inc.
- Claims
- 4
- CPC classes
- A61K, A61K38/00, A61K38/16, A61P
Quick answer
US 8754051 (Peptide modulators of the δPKC interaction with the d subunit of F1Fo ATP synthase/ATPase and uses thereof) is held by Georgia Regents Research Institute, Inc.. Status: granted. Granted Jun 17, 2014. Expires Jun 12, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Georgia Regents Research Institute, Inc.
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K38/00, A61K38/16, A61P, A61P29/00, A61P3/10
More from Georgia Regents Research Institute, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 8754051?
US 8754051 (Peptide modulators of the δPKC interaction with the d subunit of F1Fo ATP synthase/ATPase and uses thereof) is held by Georgia Regents Research Institute, Inc.. Status: granted. Granted Jun 17, 2014. Expires Jun 12, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8754051?
Georgia Regents Research Institute, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 8754051 expire?
Our index shows an expiration date of Jun 12, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.